Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Mar 20, 2015 | VP Clinical Ops & Data Mgmt | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 1,459 | -- | 8,341 | |
| Mar 20, 2015 | VP Clinical Ops & Data Mgmt | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 715 | -- | 9,026 | |
| Mar 20, 2015 | VP Clinical Ops & Data Mgmt | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 5,611 | -- | 39,389 | |
| Feb 24, 2015 | Sr Vice President Discovery | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Form 4 | 41,441 | $8.43 | 828,840 | |
| Feb 13, 2015 | Director, Chairman & CEO | Other acquisition or disposition | Form 5 | -- | -- | 64,895 | |
| Jan 23, 2015 | Sr Vice President Discovery | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Form 4 | 41,441 | $8.10 | 870,281 | |
| Jan 05, 2015 | VP, Program Management | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 4,667 | $9.00 | 54,667 | |
| Jan 05, 2015 | VP, Program Management | Open market or private sale of non-derivative or derivative security | Form 4 | 4,667 | $9.00 | 50,000 | |
| Jan 05, 2015 | VP, Program Management | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 4,667 | -- | -- | |
| Jan 02, 2015 | Chief Financial Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 90,000 | -- | 90,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.